Non-HDL-C

More documents

Recommendations

Info

The LDL level at which cardiovascular event rate may approach ZERO is estimated to be 60mg/dl for primary prevention and 30 mg/dl for secondary prevention 1. McKenney. Am J Ther. 2004;11:54-59; 2. Jones et al for the STELLAR Study Group. Am J Cardiol. 2003;92:152-160; 3. Olsson et al. Am Heart J. 2002;144:1044-1051; 4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486-2497.
CAD risk can be reduced to a maximum of approximately 35% with current statin and/or fibric acid derivates Leaving 65% risk reduction to be gained, <strong>HDL</strong>-C increasing strategies are becoming increasingly important 1 1 Duffy & Rader Circulation 2006; 113
Page 1 and 2: Current Targets and Treatment Gaps
Page 3 and 4: Fasting and Nonfasting TG: Equally
Page 5 and 6: Role of Low HDL-C in Residual Cardi
Page 7 and 8: Association Between LDL-C, Non-HDL-
Page 9 and 10: CHD risk predicted by HDL and LDL i
Page 11 and 12: New CV events in MI patients with n
Page 13 and 14: Percentage of patients reaching ADA
Page 15: IS THERE AN ASYMPTOTIC LIMIT FOR LD
Page 19 and 20: Should both HDL-C and LDL- C be tar
Page 21: Should HDL Raising Be a Target for
Page 28 and 29: Recommendations for management of d
Page 30: NCEP ATPIII, AHA, and ADA: Recommen
Page 33 and 34: NCEP ATP III Guidelines (Cont.) If
Page 35 and 36: American Diabetes Association Stand
Page 37 and 38: Target Levels Risk Level Initiate t
Page 44 and 45: Conclusion Non pharmacological stra

Non-HDL-C

Create successful ePaper yourself

Delete template?

Save as template?